XING Genomic Services receives NATA accreditation for Pillar Biosciences HRD Gene Panel Enabling Cost-Effective PARPi-response Prediction
Brisbane, Australia–XING Genomic Services, a subsidiary of XING Technologies, is pleased to announce that they have received NATA accreditation effective from July 2021 to offer clinical cancer genetic testing using the Pillar Biosciences HRD (homologous recombination deficiency) assay. This test identifies cancer patients that have tumours with impaired DNA repair capability, making them more likely […]
Pillar Biosciences Receives Premarket Approval from FDA for its oncoReveal™ Dx Lung and Colon Cancer Assay
NATICK, Mass. & SHANGHAI–(BUSINESS WIRE)– Pillar Biosciences, an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the U.S. Food and Drug Administration (FDA) has given Premarket Approval (PMA) to its oncoReveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the qualitative detection of somatic mutations in DNA derived from […]
Pillar Biosciences appoints Dr. Eric Lai to its Board of Directors
NATICK, Mass. & SHANGHAI–(BUSINESS WIRE)–Pillar Biosciences, an innovative next-generation sequencing (NGS) solutions in-vitro diagnostics (IVD) company, today announced the appointment of Eric Lai, Ph.D. to the Board of Directors. Dr. Lai brings more than 20 years of experience in drug and IVD molecular diagnostic development to the team at Pillar Biosciences. Dr. Lai was previously […]
Pillar Biosciences and PierianDx Announce Partnership to Support Precision Cancer Care
ST. LOUIS & NATICK, Mass., Oct 15, 2020 – PierianDx, the leading clinical genomics informatics company, and Pillar Biosciences, a leading next-generation sequencing clinical oncology company, today announced a partnership that enables Pillar Biosciences to sell directly the PierianDx clinical genomic report in combination with its cancer profiling assays. Under the agreement, PierianDx will integrate […]
Pillar Biosciences welcomes new independent board member Robert Forrester
Natick, MA, Oct 1, 2020 — Pillar Biosciences, a next-generation sequencing (NGS) clinical cancer diagnostics company, today announced the addition of a new independent board member, Robert Forrester. Mr. Forrester has over two decades of experience in C-level positions in the pharmaceutical industry. Mr. Forrester joins a team of pragmatic experts in diagnostics and oncology […]
NextGen Omics UK Virtual Conference
September 25, 2020 12:30-13:30 CST NextGen Omics Series UK: Virtual November 4-6th, 2020, GMT Join us for this year’s NextGen Omics Conference, now online Share on facebook Share on twitter Share on linkedin WATCH NOW Join Pillar Biosciences and over 1000 other leaders in NGS at this year’s NextGen Omics UK Conference, now online. Visit […]
This small academic lab ramped up in-house NGS testing despite limited resources, and you can too
“There has been sort of this push to make genomics a send-out endeavor…and we are pushing back.” Dr. Cynthia Schandl is the director of a genomics lab at the Medical University of South Carolina (MUSC). Despite the small size of her team–three senior staff, three technologists, and a few supporting staff—they support the largest academic […]
Finding flexibility in a resource limited world: Online presentation
Time and resource optimization are top-of-mind for many clinical labs working with NGS. As a resource for clinical researchers and labs, we revisit this presentation on panel evaluation. In this presentation, initially shared as a corporate workshop at AMP 2019, Cynthia Schandl, MD, PhD and Julie Hirschhorn, PhD evaluate the flexibility, affordability, and ease-of-use of […]
The complexity of the NGS process, compounded by sample processing, results in unique challenges for clinical oncology laboratories
Increasingly, clinical samples of all types are being analyzed with the goal of matching patients to target therapies. In the summer of 2017, Thermo Fisher received the first FDA companion diagnostic test approval for multiple non-small cell lung cancer (NSCLC) therapies, while Foundation Medicine received FDA approval for their FoundationFocus CDxBRCA as a companion diagnostic for an ovarian cancer […]
Pillar NGS panels go global with increased platform versatility
Pillar Biosciences, an NGS diagnostics company based in Boston, MA, announced today that Pillar® ONCO/Reveal™ NGS panels are now compatible with Illumina®, Ion Torrent™, and MGI™ sequencing platforms. Additionally, Pillar has entered into a co-marketing agreement with MGI that will highlight the compatibility between Pillar’s NGS assays and MGI’s sequencing platform-agnostic sample prep robotics. “With […]